Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.

Syrios J, Kouroussis C, Kotsakis A, Kentepozidis N, Kontopodis E, Kalbakis K, Vardakis N, Hatzidaki D, Polyzos A, Georgoulias V; GU Working Group of the Hellenic Oncology Research Group (HORG), Athens, Greece.

Minerva Ginecol. 2019 Feb 6. doi: 10.23736/S0026-4784.19.04249-7. [Epub ahead of print]

PMID:
30727721
2.

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).

Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2014 Dec;148(3):591-7. doi: 10.1007/s10549-014-3202-5. Epub 2014 Nov 16.

PMID:
25399229
3.

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.

Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group.

Ann Oncol. 2010 Jan;21(1):48-54. doi: 10.1093/annonc/mdp498. Epub 2009 Nov 11.

PMID:
19906761
4.

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).

Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2010 Jan;119(1):95-104. doi: 10.1007/s10549-009-0468-0. Epub 2009 Jul 28.

PMID:
19636702
5.

Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study.

Kouroussis C, Vamvakas L, Vardakis N, Kotsakis A, Kalykaki A, Kalbakis K, Saridaki Z, Kentepozidis N, Giassas S, Georgoulias V.

Oncology. 2009;76(2):112-7. doi: 10.1159/000192586. Epub 2009 Jan 14.

PMID:
19142045
6.

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.

Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2008 Aug;62(3):449-56. Epub 2007 Oct 25.

PMID:
17960381
7.

Carcinoma of sigmoid colon after ureterosigmoidostomy.

Melliou A, Theocharidis G, Helis L, Makridis J, Patakiouta F, Kouroussis C.

J BUON. 2005 Oct-Dec;10(4):551-3.

PMID:
17357215
8.

Malignant peripheral nerve-sheath tumor of the left cerebello-pontine angle: case report.

Melliou A, Karamouzis J, Helis L, Mouzakiti A, Theocharidis G, Karkavelas G, Kouroussis C.

J BUON. 2006 Jul-Sep;11(3):367-8. No abstract available.

PMID:
17309166
9.

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.

Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V.

Breast Cancer Res. 2006;8(4):R36.

10.

Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D.

J Clin Oncol. 2006 Aug 10;24(23):3756-62. Epub 2006 Jun 12.

PMID:
16769987
11.

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.

Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group.

Cancer Chemother Pharmacol. 2006 Dec;58(6):742-8. Epub 2006 May 23.

PMID:
16718470
12.

Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.

Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulias V.

Oncology. 2005;69(5):384-90. Epub 2005 Nov 24.

PMID:
16319509
13.

Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.

Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, Christofilakis C, Xenidis N, Georgoulias V, Polyzos A.

Oncology. 2005;69(4):348-53. Epub 2005 Nov 16.

PMID:
16293974
14.

A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.

Souglakos J, Kakolyris S, Vardakis N, Androulakis N, Mavroudis D, Vamvakas L, Kouroussis C, Agelaki S, Saridaki Z, Georgoulias V.

Cancer Invest. 2005;23(6):505-10.

PMID:
16203658
15.

Teaching cancer management to primary care health staff: the first experiences gained from Crete.

Lionis C, Samoutis G, Kouroussis C, Trigoni M, Georgoulias V.

J Cancer Educ. 2005 Spring;20(1):6-7. No abstract available.

PMID:
15876173
16.

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.

Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H.

Ann Oncol. 2005 Jun;16(6):950-7. Epub 2005 Apr 13.

PMID:
15829494
17.

A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer.

Kouroussis C, Kalbakis K, Androulakis N, Agelaki S, Vamvakas L, Malas K, Souglakos J, Vardakis N, Georgoulias V.

Anticancer Res. 2004 Nov-Dec;24(6):4217-21.

18.

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.

Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D.

J Clin Oncol. 2005 May 1;23(13):2937-45. Epub 2005 Feb 22.

PMID:
15728228
19.

Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.

Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A.

Gynecol Oncol. 2004 Dec;95(3):695-700.

PMID:
15581984
20.

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.

Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I; Lung Cancer Committee of the Hellenic Oncology Research Group.

Br J Cancer. 2004 Aug 2;91(3):482-8.

Supplemental Content

Loading ...
Support Center